The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on ...
StockStory.org on MSN
3 reasons LH is risky and 1 stock to buy instead
Labcorp currently trades at $265.08 per share and has shown little upside over the past six months, posting a middling return ...
Earlier this week, Labcorp announced the nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered for eligible Medicare and Medicare ...
View Labcorp Holdings Inc. LH stock quote prices, financial information, real-time forecasts, and company news from CNN.
Collaboration leverages Olaris' scientific leadership in transplant diagnostics and Labcorp's scientific expertise and national scale to advance post-transplant monitoring. FRAMINGHAM, Mass.
BURLINGTON, N.C.--(BUSINESS WIRE)--There is a new and convenient way for millions of individuals to assess whether they are at risk for developing diabetes. Labcorp (NYSE: LH), a leading global life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results